Latest From Vivet Therapeutics
Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
Janet Lambert, CEO of the Alliance of Regenerative Medicines recently spoke to In Vivo about the tremendous levels of investment the cell and gene therapy industries are attracting, as well as reasons why Europe excels at incubating advanced product development.
Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Western Europe
- Company Type
- Parent & Subsidiaries
- Vivet Therapeutics
- Senior Management
Jean-Philippe Combal, PhD, CEO
Gloria Gonzalez-Aseguinolaza, PhD, CSO
Susan Coles, Head, Fin.
Anne Douar, PhD, Chief Dev. Officer
Bernard Bénichou, MD, PhD, CMO
- Contact Info
29 rue Tronchet
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.